Hematologic Cancers
For patients with non-Hodgkin lymphoma (NHL) receiving chemotherapy, primary prophylaxis against febrile neutropenia (FN) can safely be administered on the same treatment day, if necessary, according to a review of patients from the Cleveland Clinic, presented at the 2013 American Society of Hematology annual meeting. Read More ›
This article discusses ongoing clinical investigations of the agent in a wide range of therapeutic areas. Read More ›
Bendamustine is currently approved for the treatment of chronic lymphocytic leukemia (CLL), and many ongoing studies are investigating its efficacy in drug combinations. Read More ›
Bendamustine has demonstrated activity as monotherapy and in combination for patients with lymphoid and hematologic as well as solid tumors. Read More ›
At the 54th Annual Meeting of the American Society of Hematology, a number of abstracts were presented demonstrating the efficacy and toxicities of bendamustine either alone or in combination with other agents for the treatment of several lymphoid malignancies such as chronic lymphocytic leukemia (CLL) and indolent as well as aggressive non-Hodgkin lymphoma (NHL). Read More ›
An investigational oral proteasome inhibitor known as MLN9708 had such promising results in phase 1 and 2 trials that it is currently in phase 3 testing. If results are positive, the drug is expected to be approved as soon as 2014. Read More ›
In August 2012, vincristine sulfate LIPOSOME injection (VSLI) (Marqibo) was granted accelerated approval by the US Food and Drug Administration (FDA) for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed after 2 or more regimens. Read More ›
Joseph C. Alvarnas, MD, discussed new drugs that might improve outcomes for relapsed/refractory acute lymphoblastic leukemia (ALL) at the National Comprehensive Cancer Network 7th Annual Congress on Hematologic Malignancies.1 Alvarnas is director of medical quality and clinical associate professor at City of Hope Comprehensive Cancer Center in Duarte, California. Read More ›
The management of relapsed/refractory acute lymphoblastic leukemia (ALL) is a vexing problem and requires extensive, aggressive supportive care throughout the course of therapy, explained Joseph C. Alvarnas, MD, City of Hope Comprehensive Cancer Center, Duarte, California, in a presentation at the National Comprehensive Cancer Network (NCCN) 7th Annual Congress on Hematologic Malignancies.1 Read More ›
The best strategy for management of low-tumor-burden follicular lymphoma (FL) following response to induction therapy is controversial. The phase 3 RESORT study compared maintenance rituximab therapy versus rituximab retreatment at disease progression, and results suggest that retreatment is the preferred approach. The study was presented at the 53rd Annual Meeting of the American Society of Hematology. The strategies achieved a similar time to treatment failure (TTTF) in this FL patient population, with no difference in quality of life or anxiety at 12 months. Read More ›